The 3-day course on the managed introduction of new drugs was organised by the Piperska group together with the Agency for Health Technology Assessment and Tariff System (AOTMiT) and WHO Europe to share experiences and case histories among health authority and health insurance company personnel, academics and those from commercial organisations from across Europe on potential ways to optimise the managed entry of new medicines. This starts pre-launch with horizon scanning and budgeting, then peri-launch including critical drug evaluation, and finally post launch including monitoring prescribing of new medicines against agreed guidance and indicators. There were also discussions on issues regarding managed entry schemes and procurement strategies including biosimilars.
|Number of pages||4|
|Journal||Expert Review of Pharmacoeconomics and Outcomes Research|
|Publication status||Published - 14 Sep 2015|
- horizon scanning
- managed entry schemes
Matusewicz, W., Godman, B., Bak Pedersen, H., Fürst, J., Gulbinovič , J., Mack, A., Selke, G., Timoney, A., Warmińska, E., & Malmström, R. E. (2015). Improving the managed introduction of new medicines: sharing experiences to aid authorities across Europe. Expert Review of Pharmacoeconomics and Outcomes Research, 15(5), 755-758. https://doi.org/10.1586/14737167.2015.1085803